Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 1

Status

Completed 29Unknown 11Recruiting 6Terminated 4Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 24Neoplasm Metastasis 6Colonic Neoplasms 6Stomach Neoplasms 5Rectal Neoplasms 5Carcinoma, Hepatocellular 4Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Adenocarcinoma Of Esophagus 3Unresectable Metastatic Colorectal Cancer 2Recurrence 2Neoplastic Cells, Circulating 2Neoplasms 2Gastrointestinal Neoplasms 2Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Ovarian Neoplasms 1Oligometastatic Gastric Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Margins of Excision 1Lung Neoplasms 1Locally-advanced Rectal Cancer 1Locally Advanced Colorectal Carcinoma 1Hyperthermia 1Gastroesophageal Junction Adenocarcinoma 1Gastroesophageal Adenocarcinoma 1Gallbladder Neoplasms 1

Interventions

Oxaliplatin 13Bevacizumab 11Capecitabine 10Fluorouracil 8Blood Specimen Collection 8Leucovorin 7Cetuximab 7Folfox protocol 6pembrolizumab 5Drug Therapy 5trifluridine tipiracil drug combination 4dostarlimab 4Nivolumab 4Irinotecan 4HMPL-013 4fludarabine 3XELOX 3Specimen Handling 3IFL protocol 3Cyclophosphamide 3Biopsy 3toripalimab 2tislelizumab 2tipiracil 2regorafenib 2pertuzumab 2envafolimab 2encorafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Colonic Neoplasms × Folfox protocol × Clear all
NCT07284849 2026-05-26

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Incyte Corporation

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GlaxoSmithKline

Phase 3 Recruiting
892 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06293625 2025-03-30

FOxTROT2France

Centre Hospitalier Universitaire Dijon

Phase 3 Recruiting
150 enrolled
Gastrointestinal

Colonic Neoplasms

NCT05534087 2024-11-29

CLAUDIA

Seoul National University Hospital

Phase 3 Recruiting
236 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT05194878 2022-01-18

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Sun Yat-sen University

Phase 3 Recruiting
840 enrolled
Gastrointestinal

Colonic Neoplasms

NCT03985891 2020-12-17

JSFOL

Xiangya Hospital of Central South University

Phase 1/2 Recruiting
40 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡